Joe Cabral

Joe joined Frazier Healthcare Partners in 2021, where he focuses on identifying and evaluating investment opportunities and creating new ventures in the life sciences. He has contributed to multiple investments since joining the firm, including NewAmsterdam Pharma (NASDAQ: NAMS) and Alpha-9 Theranostics.

Prior to joining Frazier, Joe was in venture creation at Flagship Pioneering, where he developed the science, intellectual property and corporate strategy of first-in-category life science companies. In that context, Joe played a pivotal role in the inception and development of Generate Biomedicines, a platform company leveraging machine learning for the design of protein therapeutics, where he also held operational roles in biology and corporate strategy. Prior to Flagship, Joe was an early employee at Moderna, where he aided the buildout of the computational biology function, led several research activities to better understand the biophysics of modified mRNA, and helped launch a therapeutic program in personalized cancer vaccines.

Joe received his M.B.A. from the Ross School of Business at the University of Michigan, where he received multiple awards recognizing his outstanding performance in entrepreneurship and venture capital. Joe also holds a M.S. in Genomics and B.S. in Biology from the University of Connecticut.